Shareholders that lost money on Skye Bioscience, Inc. (SKYE) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

Core Viewpoint - The Gross Law Firm is notifying shareholders of Skye Bioscience, Inc. about a class action lawsuit related to misleading statements regarding the company's lead product candidate, nimacimab, which allegedly had overstated effectiveness and prospects [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [3]. - Allegations include that the defendants made materially false and misleading statements about nimacimab's effectiveness and its clinical, regulatory, and commercial prospects [3]. - The deadline for shareholders to register for the class action is January 16, 2026, and there is no cost to participate [4]. Group 2: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].